Pharmacovigilance Challenges in Biosimilars
This session of the Biosimilars will investigate the future and FDA activities that have just been declared to incorporate upgraded following and follow-up of post promoting observation issues, arranged enhancements in AERS, and pilots of new post market drug-monitoring strategies and ADR related issues. Biosimilar rules for pharmacovigilance practice and pharmaco epidemiology are the focuses that will be laid emphasis in this session. U.S. normal yearly spending development from 2002 to 2007 was 16% for biologics, contrasted and 3.7% for drugs. In same extent pharmacovigilance for biosimilars has been nearly more than other pharmaceutical items